Van Campen Liem has assisted Eli Lilly and Company in connection with its investment in Audion Therapeutics B.V.
Hearing loss company Audion Therapeutics B.V. (Amsterdam, the Netherlands) raised an undisclosed amount in a series A round from Eli Lily and Co. (NYSE:LLY) and received rights to undisclosed compounds from the pharma in development to treat hearing loss via hair cell regeneration. Under the deal, Lilly has an option to reacquire the compounds after clinical proof of concept.
The Van Campen Liem team consisted of Edwin Liem, Cees Kersten and Wouter Casteleijn.
For more news, please go to: BioCentury news